Advanced Biomed Inc. (ADVB) · Nov 20, 2026 · Share issuance
$112K equity raise — 320,000 shares at $0.35; 1,652,133 shares currently outstanding
Advanced Biomed’s stock raise brings in $112K but adds nearly 20% dilution as its AI transition remains cash-burning.
Advanced Biomed is no longer primarily a biotech company: it has sold its historical biotechnology subsidiaries and is trying to build an AI and financial-algorithm software business through Acellent. The latest quarter showed that transition is still early—no revenue from Acellent and a $989,054 net loss—while cash was only $213,995 and operating cash use was $171,464.
The financing is small relative to the company’s funding needs. The agreement provides for up to 320,000 shares at $0.35 each, or $112,000 of gross proceeds. That is roughly 65% of the latest quarter’s operating cash burn and only about half of reported cash, so it helps near-term liquidity but does not materially de-risk the transition.
| Figure | This filing | Reference |
|---|---|---|
| Shares offered (Securities Purchase Agreement) | 320,000 | 1,652,133 outstanding |
| Gross proceeds (Securities Purchase Agreement) | $112,000 | $213,995 cash |
| Operating cash used (Liquidity and going concern) | $171,464 | $112,000 proceeds |
The cost is meaningful dilution. The company says 1,652,133 shares were issued and outstanding before the deal. Issuing the full allotment would increase the share count by about 19%, a large equity cost for a relatively modest cash injection.
This funds survival more than execution. The filing does not identify a growth investment, customer contract, or operating milestone attached to the proceeds; it mainly documents a private placement that is expected to close within two business days, subject to conditions. The company’s recent operating story is still one of integrating and monetizing Acellent rather than demonstrating traction, so the raise extends runway without changing that underlying story.
Bottom line: This is a modest liquidity buffer for an AI pivot that is still losing money, purchased with substantial dilution. It helps the company keep operating, but it does not meaningfully advance the business case and lands slightly negatively on balance.
Closing expected within two business days
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!